| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Ciphergen Biosystems, Inc. |
| 490 San Antonio Road, Palo Alto, CA 94306 * (650) 496-3770 |
| Business Description | The company develops, manufactures and markets a proprietary ProteinChip System that enables protein discovery, characterization and assay development to provide a better understanding of biological functions at the protein level. |
| Offering Information Company has | |||
| Trading As | CIPH (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 3/20/00 |
| Domestic Shares Offered | 5,500,000 | Offer Date | 9/28/00 |
| Foreign Shares Offered | 0 | Filing Range | $14.00 - $16.00 |
| Company Shares | 5,500,000 | Offer Price | $16.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.120 |
| Gross Proceeds | $88,000,000 | Selling | $0.670 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 25,130,567 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| SG Cowen | Lead Manager | (212) 495-6000 |
| ING Baring Furman Selz | Co-manager | (212) 309-8200 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-3000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 1.283 | 2.933 | 5.010 | - | - |
| Income from Oper. | - | - | -6.583 | -8.167 | -7.625 | - | - |
| Net Income | - | - | -6.809 | -8.310 | -7.681 | - | - |
| E.P.S | - | - | -1.010 | -0.720 | -0.520 | - | - |
| Revenue Growth (%) | - | - | 128.60 | 70.815 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -5.08 | - | - | ||||
| Cash Flow - Inv. | -0.92 | - | - | ||||
| Cash Flow - Fin. | 1.80 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 6.15 | Current Assets | 4.84 | Current Ratio | 1.46 |
| Total Liab. | 29.43 | Current Liab. | 3.31 | Debt Ratio | 478.72% |
| Total Equity | -23.28 | Working Cap. | 1.53 | Debt to Equity Ratio | - |
| Cash | 2.80 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, including establishment of Biomarker Discovery Centers, expansion of facilities and expansion of sales and marketing capabilities, and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm | Brobeck, Phleger & Harrison |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| T. William Hutchens | 16.20 | |
| James L. Rathman | 11.30 | |
| Falcon Technology Partners | 11.20 | |
| S.R. One, Limited | 9.70 | |
| Atlas Venture | 8.20 | |
| Tai-Tung Yip | 7.30 | |
| William E. Rich | 7.00 | |
| MDS Capital Corporation | 6.40 | |
| Note: represents ownership of 5% or more prior to the offering. | ||